Sincalide (CCK-8) Research Overview

What Is Sincalide?

Sincalide is a synthetic octapeptide corresponding to the C-terminal 8 amino acids of cholecystokinin (CCK), designated CCK-8. It is the active pharmacological fragment of the 33-amino acid CCK peptide hormone that is naturally secreted by enteroendocrine I-cells of the small intestinal mucosa in response to dietary fat and protein. Sincalide is marketed under the brand name Kinevac (Bracco Diagnostics) and is FDA-approved as a diagnostic imaging agent.

The amino acid sequence of sincalide is Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2 — a sulfated octapeptide with a molecular weight of 1143.25 Da. The sulfation of the tyrosine residue at position 2 (from the C-terminus) is essential for high-affinity binding to CCK-A (CCK1) receptors. This is a diagnostic drug, not a therapeutic drug: it is administered under clinical supervision as part of an imaging procedure, not taken chronically.

Mechanism of Action

Sincalide exerts its effects primarily through CCK-A receptors (now designated CCK1 receptors), which are expressed at high density on gallbladder smooth muscle, the sphincter of Oddi, pancreatic acinar cells, and certain brain regions. CCK1 receptor activation is Gq-coupled, triggering IP3-mediated calcium release and smooth muscle contraction.

In the biliary system, sincalide causes vigorous gallbladder smooth muscle contraction and simultaneous relaxation of the sphincter of Oddi, promoting bile ejection into the duodenum. This gallbladder contraction is the physiological event exploited in hepatobiliary scintigraphy (HIDA scanning): by quantifying how much radiolabeled tracer is expelled from the gallbladder during sincalide infusion, clinicians can calculate the gallbladder ejection fraction (GBEF) as a measure of gallbladder contractile function.

In the pancreas, sincalide stimulates acinar cell enzyme secretion (amylase, lipase, proteases), which provides the basis for its use in augmenting pancreatic secretion during secretin-stimulation testing — another approved diagnostic application.

Key Diagnostic Research

Gallbladder Ejection Fraction and Infusion Methodology

The clinical utility of sincalide in HIDA scanning depends critically on infusion technique. Early package insert guidance specifying rapid bolus injection (over 30–60 seconds) was shown by Ziessman and colleagues to produce inconsistent and falsely low GBEF values due to gallbladder spasm. A landmark multicenter investigation by Ziessman et al. (Journal of Nuclear Medicine, 2010) established that sincalide 0.02 mcg/kg infused over 60 minutes produces the most reproducible, physiologically valid GBEF measurements.

That multicenter study (JNM 2010; snmjournals.org) enrolled patients across multiple institutions and established that the lower limit of normal GBEF for the 60-minute infusion protocol is 38%. A GBEF below 38% with this standardized methodology is considered abnormal and may indicate biliary dyskinesia or chronic acalculous cholecystitis in the appropriate clinical context.

Society Consensus and Standardization

An interdisciplinary consensus statement on cholecystokinin-cholescintigraphy published in Clinical Gastroenterology and Hepatology (2012) codified best practices for sincalide administration, GBEF interpretation, and correlation with clinical outcomes. The consensus supported the 60-minute infusion as the standard approach. Drane WE and Johns DA published earlier work on sincalide-augmented quantitative hepatobiliary scintigraphy that also informed the normalization of GBEF methodology.

Pancreatic Imaging Applications

Sincalide can be administered after intravenous secretin to augment pancreatic secretory output during ERCP or endoscopic collection procedures, allowing measurement of pancreatic exocrine function. This application is less common than the gallbladder HIDA indication but remains within the scope of Kinevac's approved labeling.

Pharmacokinetics

Sincalide is administered intravenously and acts within minutes on smooth muscle targets. It is rapidly eliminated from plasma by endopeptidases with an estimated plasma half-life of 2.5 minutes. There is no oral bioavailability; the peptide is degraded in the gastrointestinal tract. Elimination is primarily via proteolytic degradation rather than renal excretion of intact peptide.

The gallbladder contraction response begins within 5–10 minutes of starting a slow infusion and reaches maximum at approximately 20–40 minutes. Because the drug is cleared rapidly, the contraction stimulus is maintained only during the infusion, making infusion rate and duration the primary determinants of the GBEF response.

FDA-Approved Indications and Diagnostic Dose

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

Sincalide is a diagnostic imaging agent, not a therapeutic drug. It is administered once during an imaging procedure under clinical supervision. The FDA label for Kinevac specifies the following uses and doses:

1. Gallbladder contraction (HIDA scan / cholescintigraphy): The FDA label specifies 0.02 mcg/kg administered intravenously. Current consensus guidelines (Ziessman et al., JNM 2010; interdisciplinary consensus 2012) specify this dose should be infused over 60 minutes for optimal GBEF measurement rather than the rapid bolus injection described in the original package insert.

2. Acceleration of intestinal transit of barium (radiological studies): The FDA label specifies 0.04 mcg/kg IV over 30–60 seconds, which can reduce transit time for barium follow-through studies.

3. Stimulation of pancreatic secretions with secretin (secretin-sincalide test): The FDA label specifies 0.02 mcg/kg IV administered over 30–60 seconds following secretin administration.

Storage and Stability

Kinevac is supplied as a lyophilized powder in single-dose vials. Per the FDA label, vials should be stored at controlled room temperature (approximately 15–25 °C), protected from light. The powder is reconstituted with 5 mL of Sterile Water for Injection immediately before use. Once reconstituted, the solution should be used promptly; any unused portion should be discarded. Reconstituted sincalide should not be stored.

Safety Considerations in Diagnostic Use

The most common adverse effects reported with sincalide are abdominal discomfort, cramping, nausea, and flushing, which typically reflect vigorous gallbladder contraction and are more pronounced with rapid bolus injection than with slow infusion. These effects are transient and self-limited. Rapid bolus injection can also cause significant nausea and vomiting, which is another reason current consensus favors the 60-minute slow infusion protocol.

Sincalide should not be administered to patients with active gallstone disease where contraction could precipitate biliary colic, or to patients with known obstruction of the bile duct, unless clinically indicated and supervised. Hypersensitivity reactions to sincalide or any component of the formulation are a contraindication per the FDA label.

What Sincalide Is Not

Sincalide is not a therapeutic drug taken for ongoing treatment of any condition. It is not an appetite suppressant or weight-loss agent, despite CCK's established role as a satiety signal in the literature; sincalide is not used or approved for that purpose. It is not a digestive enzyme supplement. It is not a growth hormone secretagogue or any other class of peptide commonly encountered in research-peptide markets.

Sincalide (CCK-8) should not be confused with full-length CCK-33 or CCK-58, which are endogenous peptides with broader receptor occupancy profiles. The unsulfated form of CCK-8 has approximately 1000-fold lower receptor affinity than the sulfated form and is not the active pharmaceutical ingredient in Kinevac.

References

See citations below.